3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
485
Triple Negative Breast Neoplasms
28
Carcinoma, Non-Small-Cell Lung
22
Breast Neoplasms, Male
22
Neoplasms
20
Inflammatory Breast Neoplasms
20
Neoplasm Metastasis
19
Prostatic Neoplasms
17
HER2-positive Breast Cancer
16
Ovarian Neoplasms
13
Lung Neoplasms
13
Stomach Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
10
Head and Neck Neoplasms
9
Melanoma
8
Esthesioneuroblastoma, Olfactory
8
Carcinoma, Renal Cell
8
Urinary Bladder Neoplasms
7
Small Cell Lung Carcinoma
7
Salivary Gland Neoplasms
7
Pancreatic Neoplasms
7
Esophageal Neoplasms
7
Neutropenia
6
Breast Diseases
6
Sarcoma
5
Carcinoma, Ovarian Epithelial
5
Uterine Cervical Neoplasms
4
Primary Breast Cancer
4
Pathologic Complete Response
4
Endometrial Neoplasms
4
Interventions
pembrolizumab
2
Trastuzumab
1
Quality of Life
1
Patient Reported Outcome Measures
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Immunotherapy
1
Imatinib Mesylate
1
Drug Therapy
1
Docetaxel
1
Biological Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Adenoid Cystic
×
Docetaxel
×
Breast
×
Clear all
NCT04140526
2025-05-23
PRESERVE-001
OncoC4, Inc.
Phase 1/2
Active not recruiting
733 enrolled